Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014–2015 Northern Hemis...

Full description

Bibliographic Details
Main Authors: Zhaojun Mo, Yi Nong, Shuzhen Liu, Ming Shao, Xueyan Liao, Kerry Go, Nathalie Lavis
Format: Article
Language:English
Published: Taylor & Francis Group 2017-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
adult
elderly
children
clinical trial
immunogenicity
safety
trivalent influenza vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2017.1285475

Internet

http://dx.doi.org/10.1080/21645515.2017.1285475

Similar Items